Research notes: Tips for navigating federal funding from the lab to the internet

houston voices

Every researcher needs a Digital Persistent Identifier.

As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers – and having one will be mandated for those receiving federal funding. Let’s take a deeper look at why this number is so important. We’ll also compare the different platforms— ORCID, Web of Science, Scopus and Google Scholar — so that you can be sure your publications, presentations, peer reviews and even information about who is citing you are being properly stored and accessed.

ORCID

There are many types of profiles and DPIs that can meet your needs, but there’s no silver bullet. Placing your work onto multiple platforms is necessary according to Andrea Malone, Research Visibility and Impact Coordinator at UH Libraries. She cautions researchers to “be realistic about how many identifiers you can maintain.”

The most popular is ORCID, which stands for Open Researcher and Contributor ID. It’s free to set up, and there is no chance of accidentally or on-purpose having multiple ORCID accounts – it’s assigned to you like a social security number and follows you, the researcher. This comes in particularly especially handy for researchers with common names.

An identifier is federally mandated for those receiving governmental funds. It is not specified that ORCID must be that identifier. For example, according to Malone: “a Web of Science profile also assigns an identifier, which would also satisfy the mandate.” But most researchers choose ORCID because it’s publicly available with no access restrictions.

While an ORCID number is free for researchers, there is a subscription fee for an institution to be associated with ORCID. Information will not pre-populate in an ORCID profile and it doesn’t track citation counts – it only shows what you put in. There are, however, linking wizards that allow you to link from Web of Science and Scopus to your ORCID account. If you choose this option, citations will automatically populate in your ORCID profile. It’s up to the researcher to doublecheck to be sure the information has automated, however.

Google Scholar

Google Scholar is a profile, not an identifier, so it does not comply with federal funding requirements. It is free, however, and it pulls from the open web. You can choose to have your list of articles updated automatically, review the updates yourself or manually update your articles at any time. Google Scholar also specifies which articles are open access. A PDF or HTML icon will appear on the righthand side of each citation for one to download articles.

Web of Science Vs. Scopus

Scopus is known for covering more journals and a wider range of metrics to evaluate research impact than Web of Science. Different platforms are a go-to for certain disciplines – for example, Web of Science is usually associated with hard sciences, although investigators in the social sciences and humanities also place their work on this platform from time to time. It’s a good idea to check out which platforms others in your discipline are using for their profiles.

Staying up-to-date

Of course, DPIs don’t work as intended unless researchers keep their profiles current. That means you need to check your profile after every publication and every time you switch to a new institution. Just as you would update your CV, you must update your ORCID or other DPI profile.

One tactic Malone suggests is setting a schedule either biweekly or monthly to check all your profiles. “One thing that’s helpful is that with all of them, you can set up alerts and create an alert as often as you want,” Malone goes on. “At that time, the program will scrawl the content within the source and alert you to anytime any of your publications appear in their database.”

The Big Idea

No one tool can paint a complete picture of all your scholarship. Be strategic and intentional about which platforms you use. Consider your audience, the platforms others in your discipline use and make sure you have an ORCID profile to comply with the federal mandate. But be careful not to sign up for more than you can feasibly maintain and keep current.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

Energy systems such as nuclear and geothermal
Energy supply chains
Energy-transition fuel and technology
Traditional energy

“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME